SPRI | Locoregional Radionuclide Cancer Therapy: Clinical And Scientific Aspects (2021 EN)

Discussion in 'Medicine' started by Kanka, Mar 27, 2021.

  1. Kanka

    Kanka Well-Known Member Loyal User

    Messages:
    13,502
    Likes Received:
    359
    Trophy Points:
    83
    [​IMG]

    Author: Franklin C.L. Wong (Editor)
    Full Title: Locoregional Radionuclide Cancer Therapy: Clinical And Scientific Aspects
    Publisher: Springer; 1st ed. 2021 edition (December 8, 2020)
    Year: 2021
    ISBN-13: 9783030562670 (978-3-030-56267-0), 9783030562663 (978-3-030-56266-3)
    ISBN-10: 3030562670, 3030562662
    Pages: 268
    Language: English
    Genre: Medicine: Nuclear Medicine
    File type: EPUB (True), PDF (True)
    Quality: 10/10
    Price: 145.59 €


    This book reviews locoregional radionuclide cancer therapies (LRCT). Proving an increasingly viable alternative to radiotherapy, radionuclide therapy includes a diversity of choices of well characterized biochemical and physiologic target molecules. The delivery and retention of radionuclides may be monitored by advanced imaging for exact tissue localization and for real-time dosimetry to enable personalized precision medicine. Radiopharmaceuticals in human cancer therapies are typically delivered in systemic routes but can also be designed for locoregional routes to harness pharmacokinetic advantages of higher payload and lower systemic toxicities. This book explores the latest advancements and clinical considerations of the locoregional approach.

    Throughout the chapters, the clinical and scientific bases of cancer treatment and the locoregional use of radionculides are explored. Mathematical models of radiation dosimetry of locoregional radionculdies on tissues are studied using common models for multiple commercially available radionuclides. Rodent and canine tumor models of LRCT are compared for selected radionuclides and radiopharmaceuticals. The practical aspects of radiopharmaceuticals production, marketing, transport, as well as radiation protection are reviewed. Finally, the combination of LRCT with immunotherapy and other cancer therapies and prospective future use of LRCT are discussed.

    This is a guide for practicing nuclear physicians, interventional radiologists, radiation oncologists, radiation scientists, veterinarians and oncologists to expand their knowledge base and to prepare for designing locoregional radionuclide cancer therapies in animals and in humans.

    -------------